Compare Novartis AG (NVS) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Royal Caribbean Cruises Ltd — how do they compare? Novartis AG trades at $143.71 (market cap $268.57B), while Royal Caribbean Cruises Ltd trades at $278.68 (market cap $75.26B). The key difference: Novartis AG is far larger — about 3.6× Royal Caribbean Cruises Ltd's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Royal Caribbean Cruises Ltd for 85 Days on average.
| NVS | RCL | |
|---|---|---|
Market Cap | $268.57B | $75.26B |
Volume | 1,532,573 | 1,958,628 |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $348.03 |
52-Week Low | $121.80 | $230.30 |
Typical Hold Time | 82 Days | 85 Days |
Enterprise Value | $309.89B | $97.91B |
Dividend Yield | 3.31% | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.
The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.
Royal Caribbean (RCL) trades at $280.65, down 0.61% on the day, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 2025 revenue of $17.93B, net income of $4.27B (23.54% margin), and consistent earnings beats in recent quarters. Recent news highlights include a $3B investment in Sandals Resorts and positive analyst sentiment with 52.83% buy ratings.
RCL presents a compelling growth story with strong profitability and expansion initiatives, though risks include high debt levels and fuel cost exposure. The consensus price target of $346.67 suggests 23.5% upside potential, supported by improving cash flow trends and strategic diversification into resort operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
